En trminos de dosificacin, el tratamiento con tirzepatide se inicia habitualmente con una dosis de 2,5 mg administrada por va subcutnea una vez por semana
Protects & feeds cells Reduces cell death, boosts blood vessel growth, and calms scarring signals
Gastric Emptying in Patients with Well-Controlled Type 2 Diabetes Compared with Young and Older Control Subjects Without Diabetes
Preparation of soybean protein-based nanoparticles and its application as encapsulation carriers of bioactive substances
In one such study, an obese female in her early twenties who had been taking semaglutide for weight loss for four months started to develop patches of hair loss after three months (on an increase in dose from 0.25 to 0.5 mg weekly)
Key Takeaways for Patients and Providers For Patients: Bariatric surgery is an important first step when both conditions are present Expect different weight loss patterns in lipedematous areas Symptoms may improve but might not completely resolve Additional specialized treatments may still be necessary For Healthcare Providers: Screen for lipedema in bariatric surgery candidates Set appropriate expectations about outcomes Coordinate care between bariatric and lipedema specialists Monitor for persistent symptoms that may indicate underlying lipedema For Treatment Planning: Address obesity before lipedema-specific interventions Implement comprehensive conservative measures Consider staged treatment approaches Plan for the potential need for additional therapies Understanding the relationship between bariatric surgery and lipedema ensures that patients receive comprehensive care addressing both conditions, leading to better outcomes and more realistic expectations throughout their treatment journey.
)
